Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Defibrotide Prophylaxis for TA-TMA in Neuroblastoma
NCT06182410Phase 2Withdrawn
- Sponsor
- University of California, San Francisco
- Start
- Aug 2024
- Primary completion
- May 2027
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of defibrotide in transplant-associated thrombotic microangiopathy (TA-TMA), sponsored by University of California, San Francisco. Planned start Aug 2024; status: withdrawn.
02
Drugs
defibrotide
03
Conditions
transplant-associated thrombotic microangiopathy (TA-TMA)
Beyond the preview
Go deeper on NCT06182410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06182410.